Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors.

Molecular cancer therapeutics - 1 Dec 2002

Kim Jung-Sik, Crooks Heather, Foxworth Aaron, Waldman Todd

Abstract excerpt

Activation of beta-catenin is a critical step in the pathogenesis of many common human cancers and is the initiating event in adenocarcinoma of the colon. Because activation of beta-catenin provides a gain-of-function, it is tempting to speculate that specific pharmacological inhibition of activated beta-catenin might reverse the tumorigenic properties of human cancer cells and therefore form the basis of an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Colonic Neoplasms
Share to Cytoskeletal Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Mice, SCID

Share to Neoplasm Transplantation

Share to Trans-Activators

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 12516970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors.PMID 12516970Read ↗

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors.Semantic proximity Read ↗

The potential of targeting Wnt/β-catenin in colon cancerSemantic proximity Read ↗

ShRNA-mediated gene silencing of β-catenin inhibits growth of human colon cancer cellsSemantic proximity Read ↗

Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells.Semantic proximity Read ↗

Targeting the Wnt/β-catenin signal pathway for the treatment of gastrointestinal cancer: Potential for advancementSemantic proximity Read ↗

Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.Semantic proximity Read ↗

Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling β-catenin signaling in cancer-initiating cellsSemantic proximity Read ↗

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cellsSemantic proximity Read ↗

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.Semantic proximity Read ↗

Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.Semantic proximity Read ↗

Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells.Semantic proximity Read ↗

Wnt signaling as a therapeutic target for cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.